Literature DB >> 29686157

Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.

Helio S Sader1, Glenn E Dale2, Paul R Rhomberg3, Robert K Flamm3.   

Abstract

Murepavadin (formerly POL7080), a 14-amino-acid cyclic peptide, and comparators were tested by the broth microdilution method against 1,219 Pseudomonas aeruginosa isolates from 112 medical centers. Murepavadin (MIC50/90, 0.12/0.12 mg/liter) was 4- to 8-fold more active than colistin (MIC50/90, 1/1 mg/liter) and polymyxin B (MIC50/90, 0.5/1 mg/liter) and inhibited 99.1% of isolates at ≤0.5 mg/liter. Only 4 isolates (0.3%) exhibited murepavadin MICs of >2 mg/liter. Murepavadin was equally active against isolates from Europe, the United States, and China.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  China; POL7080; Polyphor; Pseudomonas aeruginosa; antimicrobial resistance; cyclic peptide; cyclopeptide; murepavadin

Mesh：

Substances：

Year:  2018        PMID： 29686157      PMCID： PMC6021639          DOI： 10.1128/AAC.00311-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 2.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

3.  Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012.

Authors:  Helio S Sader; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  Int J Antimicrob Agents       Date:  2014-02-07       Impact factor: 5.283

4.  Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.

Authors:  Helio S Sader; Michael D Huband; Mariana Castanheira; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

5.  Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.

Authors:  Scott T Micek; Ann E Lloyd; David J Ritchie; Richard M Reichley; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

6.  Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses.

Authors:  Achim Wach; Klaus Dembowsky; Glenn E Dale
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

7.  Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa.

Authors:  Nityakalyani Srinivas; Peter Jetter; Bernhard J Ueberbacher; Martina Werneburg; Katja Zerbe; Jessica Steinmann; Benjamin Van der Meijden; Francesca Bernardini; Alexander Lederer; Ricardo L A Dias; Pauline E Misson; Heiko Henze; Jürg Zumbrunn; Frank O Gombert; Daniel Obrecht; Peter Hunziker; Stefan Schauer; Urs Ziegler; Andres Käch; Leo Eberl; Kathrin Riedel; Steven J DeMarco; John A Robinson
Journal:  Science       Date:  2010-02-19       Impact factor: 47.728

8.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.

Authors:  Lindsey M Weiner; Amy K Webb; Brandi Limbago; Margaret A Dudeck; Jean Patel; Alexander J Kallen; Jonathan R Edwards; Dawn M Sievert
Journal:  Infect Control Hosp Epidemiol       Date:  2016-08-30       Impact factor: 3.254

Review 9.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 10.  New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?

Authors:  H Wright; R A Bonomo; D L Paterson
Journal:  Clin Microbiol Infect       Date:  2017-09-08       Impact factor: 8.067
View more
  9 in total

1.  Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics.

Authors:  Miquel B Ekkelenkamp; Rafael Cantón; María Díez-Aguilar; Michael M Tunney; Deirdre F Gilpin; Francesca Bernardini; Glenn E Dale; J Stuart Elborn; Jumamurat R Bayjanov; Ad Fluit
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 2.  Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens.

Authors:  Flora Cruz-López; Adrian Martínez-Meléndez; Rayo Morfin-Otero; Eduardo Rodriguez-Noriega; Héctor J Maldonado-Garza; Elvira Garza-González
Journal:  Front Cell Infect Microbiol       Date:  2022-05-20       Impact factor: 6.073

3.  Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment.

Authors:  Glenn E Dale; Atef Halabi; Marc Petersen-Sylla; Achim Wach; Christian Zwingelstein
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 4.  Emerging therapies against infections with Pseudomonas aeruginosa.

Authors:  Burkhard Tümmler
Journal:  F1000Res       Date:  2019-08-07

5.  Mutations in pmrB Confer Cross-Resistance between the LptD Inhibitor POL7080 and Colistin in Pseudomonas aeruginosa.

Authors:  Keith P Romano; Thulasi Warrier; Bradley E Poulsen; Phuong H Nguyen; Alexander R Loftis; Azin Saebi; Bradley L Pentelute; Deborah T Hung
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

6.  Emergent Polymyxin Resistance: End of an Era?

Authors:  Zekun Li; Yuping Cao; Lingxian Yi; Jian-Hua Liu; Qiwen Yang
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

Review 7.  Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020.

Authors:  Neha K Prasad; Ian B Seiple; Ryan T Cirz; Oren S Rosenberg
Journal:  Antimicrob Agents Chemother       Date:  2022-04-26       Impact factor: 5.938

Review 8.  Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.

Authors:  María Escobar-Salom; Gabriel Torrens; Elena Jordana-Lluch; Antonio Oliver; Carlos Juan
Journal:  Biol Rev Camb Philos Soc       Date:  2022-01-18

Review 9.  Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.

Authors:  Corneliu Ovidiu Vrancianu; Irina Gheorghe; Elena-Georgiana Dobre; Ilda Czobor Barbu; Roxana Elena Cristian; Marcela Popa; Sang Hee Lee; Carmen Limban; Ilinca Margareta Vlad; Mariana Carmen Chifiriuc
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 6.208
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.